Sleeman Allyson, Clements Jennifer N
Department of Pharmacy, University Health Care System, Augusta, GA.
Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC.
Am J Health Syst Pharm. 2019 Jan 25;76(3):130-135. doi: 10.1093/ajhp/zxy022.
The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed.
A MEDLINE search was conducted for full text English-language articles, using the terms abaloparatide, parathyroid hormone, and osteoporosis. Published articles pertinent to the short- and long-term efficacy and safety of abaloparatide among postmenopausal women with osteoporosis were reviewed and summarized. Based on randomized, placebo-controlled and active-comparator studies, abaloparatide can reduce the risk of new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Abaloparatide can also significantly increase bone mineral density (BMD) at the total hip, femoral neck, and lumbar spine. Patients receiving abaloparatide experience faster and more robust changes in BMD compared to those receiving teriparatide. Overall, abaloparatide is well tolerated with a mild adverse effect profile, including dizziness, headache, nausea, and palpitations. Additionally, there is a lower incidence of hypercalcemia with abaloparatide than with teriparatide. At this time, the differences demonstrated between abaloparatide and teriparatide would not be considered clinically significant. Larger and more robust studies are needed to determine future clinical significance of abaloparatide compared with other agents for use in the postmenopausal osteoporotic population.
Abaloparatide is an effective anabolic agent to improve bone formation and resorption amongst postmenopausal women with osteoporosis. Based on its clinical evidence, abaloparatide can result in greater BMD increases and less hypercalcemia compared with the only current marketed anabolic agent, teriparatide. Adverse events associated with abaloparatide are generally mild in nature and include nausea, dizziness, headache, and palpitations.
对abaloparatide（一种用于治疗高骨折风险绝经后女性骨质疏松症的甲状旁腺激素相关蛋白类似物）的疗效和安全性进行综述。
使用abaloparatide、甲状旁腺激素和骨质疏松症等术语在MEDLINE中检索全文英文文章。对已发表的关于abaloparatide在绝经后骨质疏松症女性中的短期和长期疗效及安全性的文章进行了综述和总结。基于随机、安慰剂对照和活性对照研究，abaloparatide可降低绝经后骨质疏松症女性发生新的椎体和非椎体骨折的风险。Abaloparatide还可显著增加全髋、股骨颈和腰椎的骨矿物质密度（BMD）。与接受特立帕肽的患者相比，接受abaloparatide的患者BMD变化更快且更显著。总体而言，abaloparatide耐受性良好，不良反应轻微，包括头晕、头痛、恶心和心悸。此外，abaloparatide引起高钙血症的发生率低于特立帕肽。目前，abaloparatide和特立帕肽之间的差异在临床上不被认为具有显著意义。需要进行更大规模和更有力的研究来确定abaloparatide与其他用于绝经后骨质疏松症人群的药物相比的未来临床意义。
Abaloparatide是一种有效的促合成药物，可改善绝经后骨质疏松症女性的骨形成和吸收。基于其临床证据，与目前唯一上市的促合成药物特立帕肽相比，abaloparatide可使BMD增加更多且高钙血症更少。与abaloparatide相关的不良事件通常性质轻微，包括恶心、头晕、头痛和心悸。
